LNTH Long Call Strategy
LNTH (Lantheus Holdings, Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc.
LNTH (Lantheus Holdings, Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $6.28B, a trailing P/E of 22.38, a beta of -0.08 versus the broader market, a 52-week range of 47.25-98.27, average daily share volume of 974K, a public-listing history dating back to 2015, approximately 808 full-time employees. These structural characteristics shape how LNTH stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.08 indicates LNTH has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long call on LNTH?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current LNTH snapshot
As of May 14, 2026, spot at $95.98, ATM IV 33.30%, IV rank 1.02%, expected move 9.55%. The long call on LNTH below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 63-day expiry.
Why this long call structure on LNTH specifically: LNTH IV at 33.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a LNTH long call, with a market-implied 1-standard-deviation move of approximately 9.55% (roughly $9.16 on the underlying). The 63-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LNTH expiries trade a higher absolute premium for lower per-day decay. Position sizing on LNTH should anchor to the underlying notional of $95.98 per share and to the trader's directional view on LNTH stock.
LNTH long call setup
The LNTH long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LNTH near $95.98, the first option leg uses a $95.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LNTH chain at a 63-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LNTH shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $95.00 | $6.15 |
LNTH long call risk and reward
- Net Premium / Debit
- -$615.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$615.00
- Breakeven(s)
- $101.15
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
LNTH long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on LNTH. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$615.00 |
| $21.23 | -77.9% | -$615.00 |
| $42.45 | -55.8% | -$615.00 |
| $63.67 | -33.7% | -$615.00 |
| $84.89 | -11.6% | -$615.00 |
| $106.11 | +10.6% | +$496.30 |
| $127.33 | +32.7% | +$2,618.36 |
| $148.55 | +54.8% | +$4,740.42 |
| $169.77 | +76.9% | +$6,862.48 |
| $191.00 | +99.0% | +$8,984.54 |
When traders use long call on LNTH
Long calls on LNTH express a bullish thesis with defined risk; traders use them ahead of LNTH catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
LNTH thesis for this long call
The market-implied 1-standard-deviation range for LNTH extends from approximately $86.82 on the downside to $105.14 on the upside. A LNTH long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current LNTH IV rank near 1.02% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on LNTH at 33.30%. As a Healthcare name, LNTH options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LNTH-specific events.
LNTH long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LNTH positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LNTH alongside the broader basket even when LNTH-specific fundamentals are unchanged. Long-premium structures like a long call on LNTH are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current LNTH chain quotes before placing a trade.
Frequently asked questions
- What is a long call on LNTH?
- A long call on LNTH is the long call strategy applied to LNTH (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With LNTH stock trading near $95.98, the strikes shown on this page are snapped to the nearest listed LNTH chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LNTH long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the LNTH long call priced from the end-of-day chain at a 30-day expiry (ATM IV 33.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$615.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LNTH long call?
- The breakeven for the LNTH long call priced on this page is roughly $101.15 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LNTH market-implied 1-standard-deviation expected move is approximately 9.55%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on LNTH?
- Long calls on LNTH express a bullish thesis with defined risk; traders use them ahead of LNTH catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current LNTH implied volatility affect this long call?
- LNTH ATM IV is at 33.30% with IV rank near 1.02%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.